AstraZeneca shares rise on early U.S. approval for leukaemia drug

FRANKFURT (Reuters) - AstraZeneca shares rose 2.7% on Friday after the British drugmaker won earlier-than-expected U.S. regulatory approval for a leukaemia drug, in a challenge to rival AbbVie . AstraZeneca said late on Thursday that the U.S. Food and Drug Administration (FDA) had given its go ahead for the company's Calquence drug to treat chronic lymphocytic leukemia (CLL), one of the most common types of leukaemia in adults. The drug was approved under a new speedy review programme in..